ixazomib + cyclophosphamide + dexamethasone

This is an **all-oral, three-drug combination regimen** used primarily in the treatment of multiple myeloma and AL amyloidosis. - **Ixazomib** is a proteasome inhibitor, specifically targeting the 20S proteasome, which disrupts proteasomal protein degradation, resulting in tumor cell apoptosis. - **Cyclophosphamide** is an alkylating agent that crosslinks DNA, leading to cell death, and is commonly used as chemotherapy in hematologic cancers. - **Dexamethasone** is a synthetic glucocorticoid corticosteroid that exerts anti-inflammatory and immunosuppressive effects and can promote apoptosis in malignant lymphocytes. Together, this combination leverages complementary mechanisms: targeted protein degradation (ixazomib), DNA damage (cyclophosphamide), and anti-inflammatory/apoptotic action (dexamethasone). The regimen is notable for its convenience (all drugs administered orally), favorable toxicity profile, and use in patient populations that may not tolerate injectable or immunomodulatory treatments. It has been evaluated in clinical trials for **newly diagnosed and relapsed/refractory multiple myeloma**, and **AL amyloidosis**, showing hematologic response rates between 48–71% for MM and 63% for AL amyloidosis[1][2][3][4][5][6][7].

Brand names

Ninlaro + cyclophosphamide + dexamethasone

Other names

ICd